The specter of Alzheimer’s disease looms large in the minds of Brazilians, second only to cancer as the most feared illness, according to a recent Datafolha survey commissioned by pharmaceutical company Eli Lilly. The findings, released on March 9, 2026, reveal a significant level of anxiety surrounding the neurodegenerative condition, with 13% of respondents identifying it as their greatest health concern for loved ones. This fear, experts suggest, is deeply rooted in a lack of understanding and the persistent stigma associated with dementia.
The survey, which polled 2,002 individuals over the age of 16 across Brazil in December 2025, underscores the pervasive impact of Alzheimer’s, with 41% of Brazilians reporting they know someone affected by the disease. While cancer remains the primary health fear, cited by 75% of those surveyed, the relatively high percentage concerned about Alzheimer’s – surpassing concerns about Parkinson’s disease (1%) and AIDS (9%) – signals a growing awareness and apprehension about the condition’s devastating effects. This is particularly notable given that the average age of respondents was 44, with only 22% being 60 or older, the age group most at risk for developing dementia.
Understanding the Fear: Knowledge Gaps and Stigma
The fear surrounding Alzheimer’s isn’t simply about the disease itself, but also about the profound changes it brings to individuals and their families. Dr. Celene Pinheiro, president of the Brazilian Alzheimer’s Association (Abraz), emphasizes that a significant contributor to this fear is a lack of public knowledge about the disease. Abraz actively works to raise awareness and provide support for those affected by Alzheimer’s and other dementias in Brazil. “The fear of the disease causes many to avoid seeking help,” Dr. Pinheiro explains. “There is still the idea that dementia is a natural part of aging and that is not true. Whenever there are cognitive changes, it is necessary to investigate.” This misconception often delays diagnosis and treatment, potentially diminishing the effectiveness of interventions.
The stigma surrounding Alzheimer’s also plays a crucial role. Many individuals and families are reluctant to discuss cognitive changes, fearing judgment or discrimination. This silence can prevent early detection and access to vital resources. The reluctance to seek help is compounded by the fact that, as Dr. Claudia Suemoto, associate professor of Geriatrics at the University of São Paulo (USP) School of Medicine, notes, many people underestimate the importance of early diagnosis. Dr. Suemoto was surprised by the level of concern expressed by a relatively young demographic, suggesting a broader societal awareness of the disease’s potential impact. She also directs the Biobanco para Estudos em Envelhecimento at USP, furthering research into age-related cognitive decline.
The Challenge of Late Diagnosis in Brazil
A particularly concerning aspect highlighted by the Datafolha survey and the 2024 National Dementia Report (Renade) from the Brazilian Ministry of Health is the significant rate of underdiagnosis. The Renade report indicates that approximately 80% of dementia cases in Brazil remain undiagnosed. This delay in diagnosis not only hinders access to appropriate care but also limits opportunities for participation in clinical trials and research studies. The rate of underdiagnosis in Brazil is higher than in Europe (53.7%) and North America (62.9%), approaching levels seen in Asian countries like China and India, where rates exceed 90%.
This late diagnosis is often attributed to a normalization of cognitive decline with age. As Dr. Suemoto explains, there’s a tendency to dismiss early symptoms as simply “part of getting older.” However, she stresses that any noticeable changes in cognitive function – difficulty communicating, memory lapses, challenges with planning or problem-solving – warrant medical evaluation, regardless of age. Recognizing these subtle shifts is crucial for timely intervention.
The Importance of Early Intervention and Current Treatment Landscape
While there is currently no cure for Alzheimer’s disease, early diagnosis and intervention can significantly improve quality of life for patients and their families. The survey data reveals a surprising disconnect between the perceived importance of early diagnosis – with 99% of respondents agreeing it’s crucial – and the reality, where 60% acknowledge a significant delay between the onset of symptoms and seeking medical attention. 88% believe people typically only seek help when symptoms are already severe.
Dr. Pinheiro emphasizes that advancements in treatment mean that early intervention is more impactful than ever. “Alzheimer’s disease has no cure, but it has treatment, and the earlier it begins, the better the results.” She highlights that a combination of medication, physical activity, and cognitive stimulation can help patients maintain autonomy and a fulfilling life for years. “There are people who travel, go to the theater, to the cinema and maintain an active social life. The reality today is different from the image that many people still have of the disease.”
What is Dementia?
It’s important to understand that dementia is not a single disease, but rather an umbrella term encompassing a range of conditions characterized by a decline in cognitive function. Alzheimer’s disease is the most common form of dementia, accounting for an estimated 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Regardless of the specific type, dementia affects memory, thinking, behavior, and the ability to perform everyday tasks.
Looking Ahead: Continued Research and Public Health Initiatives
Addressing the growing concern surrounding Alzheimer’s disease in Brazil requires a multi-faceted approach. Increased public awareness campaigns are essential to dispel misconceptions and reduce stigma. Investing in research to better understand the disease’s causes and develop more effective treatments is also critical. Strengthening healthcare infrastructure to improve access to early diagnosis and specialized care is paramount. The Brazilian government, in collaboration with organizations like Abraz and research institutions like USP, must prioritize these initiatives to mitigate the impact of this devastating disease.
The next major update regarding Alzheimer’s research and treatment in Brazil is anticipated in late 2026, following the completion of several ongoing clinical trials evaluating novel therapeutic approaches. Readers are encouraged to share their experiences and perspectives on Alzheimer’s disease in the comments below, and to consult with healthcare professionals if they have concerns about cognitive health.
Related reading